Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
出版年份 2020 全文链接
标题
Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
作者
关键词
-
出版物
Cancers
Volume 12, Issue 1, Pages 195
出版商
MDPI AG
发表日期
2020-01-15
DOI
10.3390/cancers12010195
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
- (2019) Amer Alam et al. SCIENCE
- Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance
- (2019) Melissa Dolan et al. PLoS One
- Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance
- (2019) Chao-Yun Cai et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines
- (2018) Chung-Pu Wu et al. BIOCHEMICAL PHARMACOLOGY
- Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo
- (2018) Guan-Nan Zhang et al. CANCER LETTERS
- Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
- (2018) Shaocong Wu et al. Molecular Cancer
- Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells
- (2018) Wei Zhang et al. Frontiers in Pharmacology
- Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
- (2017) Giovanni Luca Beretta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structure of the human multidrug transporter ABCG2
- (2017) Nicholas M. I. Taylor et al. NATURE
- Osimertinib (AZD9291) Attenuates the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCB1 in Vitro
- (2016) Sung-Han Hsiao et al. MOLECULAR PHARMACEUTICS
- Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells
- (2015) Hiromi Sato et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Design of inhibitors of BCRP/ABCG2
- (2015) Kapil Juvale et al. Future Medicinal Chemistry
- Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1
- (2015) Sheng-qi Wang et al. Oncotarget
- Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma
- (2015) Parag P. Patwardhan et al. Oncotarget
- Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2
- (2014) Chung-Pu Wu et al. BIOCHEMICAL PHARMACOLOGY
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1
- (2013) Chung-Pu Wu et al. BIOCHEMICAL PHARMACOLOGY
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)
- (2013) Bulent Cetin et al. JOURNAL OF CHEMOTHERAPY
- Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
- (2013) Zu-Yao Yang et al. PLoS One
- GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance
- (2012) Kamlesh Sodani et al. BIOCHEMICAL PHARMACOLOGY
- The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
- (2012) Karthika Natarajan et al. BIOCHEMICAL PHARMACOLOGY
- Downregulation of mdr1 and abcg2 genes is a mechanism of inhibition of efflux pumps mediated by polymeric amphiphiles
- (2012) María L. Cuestas et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models
- (2012) Amit K. Tiwari et al. CANCER LETTERS
- Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
- (2012) Tomoyuki Mizuno et al. Drug Metabolism and Pharmacokinetics
- Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
- (2012) Suneet Shukla et al. DRUG RESISTANCE UPDATES
- Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells
- (2012) Masanobu Tsubaki et al. LEUKEMIA RESEARCH
- Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance
- (2011) Z. Shi et al. CANCER RESEARCH
- Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
- (2011) Anna Brózik et al. Expert Opinion on Drug Metabolism & Toxicology
- The Emergence of Drug Transporter-Mediated Multidrug Resistance to Cancer Chemotherapy
- (2011) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- The “Specific” P-Glycoprotein Inhibitor Tariquidar Is Also a Substrate and an Inhibitor for Breast Cancer Resistance Protein (BCRP/ABCG2)
- (2010) Pavitra Kannan et al. ACS Chemical Neuroscience
- Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
- (2010) Chung-Pu Wu et al. Current Molecular Pharmacology
- Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters
- (2009) Amit K. Tiwari et al. BIOCHEMICAL PHARMACOLOGY
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
- (2008) F.-X. Mahon et al. CANCER RESEARCH
- Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
- (2008) C.-l. Dai et al. CANCER RESEARCH
- Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
- (2008) D. K. Hiwase et al. CLINICAL CANCER RESEARCH
- Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges
- (2008) Suneet Shukla et al. Expert Opinion on Drug Metabolism & Toxicology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started